Recipharm launches standalone serialisation service
Recipharm, a leading contract development and manufacturing organisation (CDMO) has announced the launch of its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD).
The new service is designed to offer pharmaceutical companies access to Recipharm’s serialisation capabilities as a standalone service due to increasing concerns that many will not be ready for the February 2019 compliance deadline.
Moving forward Recipharm will be able to add 2D codes, human readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.
Staffan Widengren, Director of Corporate Projects at Recipharm and Head of the Global Steering Committee for Recipharm’s serialisation programme said: ”This new offering is the latest phase in our company-wide serialisation project which was launched in 2016 following a EUR 40 million investment.”
”In recent years, Recipharm has become known for taking a lead in the serialisation challenge. As the deadline gets closer we’re seeing more and more companies ask if we can provide an outsourced serialisation service that caters for the new requirements, even if the product itself is not manufactured within Recipharm it made sense to allow customers who were struggling with their existing provider to get access to our solution.”
”Implementing these measures independently across packaging lines to ensure compliance is a relatively straightforward process when using offline equipment. Our experience of serialisation means we can ensure compliance quickly and efficiently for our customers.”
Recipharm has already delivered over 1.3 million serialised and aggregated packs to markets such as China, South Korea, Saudi Arabia and Turkey, and 0.5 million packs to the US, where serialisation regulations are currently in place.
For more information about Recipharm’s serialisation services visit, www.recipharm.com/manufacturing/serialisation.
Contact information
Staffan Widengren, Director Corporate Projects, staffan.widengren@recipharm.com, +46 8 6024 475
For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com, + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
Tags: